Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Saltagen Ventures Limited, founded in 2017, is headquartered in Hong Kong. The firm specializes in early-stage investments in biotechnology startups, particularly those with the potential to scale across North America and Asia. Saltagen Ventures has established a strong presence in both Canada and China, allowing them to leverage local partnerships to support their portfolio companies.
Since its inception, Saltagen Ventures has focused on building a diverse portfolio of innovative companies, currently comprising 22 active investments. The firm emphasizes follow-on investments for successful companies, ensuring that they can continue to grow and thrive in competitive markets. Saltagen Ventures is committed to fostering the growth of biotechnology and healthcare innovations that can make a significant impact globally.
Saltagen Ventures specializes in early-stage investments, primarily in the biotechnology sector. Their investment strategy encompasses precision medicine, agricultural innovation, and nanotechnology. The firm typically invests in companies at the seed, Series A, and Series B stages, reserving capital for follow-on investments in successful ventures.
Geographically, Saltagen Ventures focuses on North America and Asia, aiming to support startups that can navigate and thrive in these markets. They seek founders who demonstrate a strong vision and the ability to execute their business plans effectively. The firm values innovative approaches to solving pressing healthcare challenges and aims to partner with companies that have scalable business models.
Saltagen Ventures has built a notable portfolio of 22 companies, including:
Joseph Fung - Managing Partner & Responsible Officer. Joseph has extensive experience in venture capital and has led numerous successful investments in the biotech sector.
Alan Chen - Investment Team. Alan brings a strong background in finance and investment analysis, focusing on identifying high-potential startups.
Emmanuel Hui - Investment Team. Emmanuel specializes in market research and due diligence, ensuring that investments align with Saltagen's strategic focus.
Jason Chiu - Investment Team. Jason has a background in biotechnology and provides insights into the technical aspects of potential investments.
Simon Lai - Investment Team. Simon focuses on operational support for portfolio companies, helping them navigate growth challenges.
Yina Chan - Investment Team. Yina has experience in startup acceleration and works closely with founders to refine their business strategies.
Henry Lau - Investment Team. Henry specializes in financial modeling and valuation, providing critical analysis for investment decisions.
Jimmy Lai - Investment Team. Jimmy has a background in healthcare and technology, contributing to the firm's focus on biotech innovations.
Elsa Lee - Investment Team. Elsa focuses on deal sourcing and relationship management within the biotech ecosystem.
Frances Law - Investment Team. Frances brings expertise in regulatory affairs, ensuring that portfolio companies navigate compliance effectively.
To pitch Saltagen Ventures, founders should email their pitch deck to info@saltagen.com. The deck should include an overview of the business model, market opportunity, competitive landscape, and team qualifications. Saltagen Ventures appreciates concise and well-structured presentations.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, but cold emails are also accepted.
Since its founding in 2017, Saltagen Ventures has actively engaged with the biotechnology ecosystem, building a diverse portfolio of innovative companies. Recent updates highlight their commitment to supporting startups that can thrive in both North American and Asian markets.
In 2023, Saltagen Ventures announced new investments in several portfolio companies, including Phase Scientific and Hylid Diagnostics, further solidifying their presence in the biotech sector. The firm continues to explore opportunities for collaboration and growth within the industry.
What investment criteria does Saltagen Ventures use?
Saltagen Ventures focuses on early-stage biotechnology companies, particularly those involved in precision medicine, agricultural innovation, and nanotechnology. They look for startups with scalable business models and strong founding teams.
How can I pitch to Saltagen Ventures?
Founders can reach out to Saltagen Ventures via email at info@saltagen.com. A well-prepared pitch deck that outlines the business model, market opportunity, and team background is recommended.
What makes Saltagen Ventures different from other investors?
Saltagen Ventures has a unique geographic focus on both North America and Asia, allowing them to leverage local partnerships and resources in these markets. Their commitment to follow-on investments also sets them apart, as they aim to support their portfolio companies throughout their growth journey.
What is the typical check size for investments?
Saltagen Ventures typically invests at the seed, Series A, and Series B stages, although specific check sizes are not publicly disclosed. They reserve capital for follow-on investments in successful companies.
What is the geographic scope of Saltagen Ventures?
The firm primarily focuses on North America and Asia, with a strong presence in Canada and China. This dual focus allows them to support startups that can scale in both regions.
What kind of post-investment involvement can founders expect?
Saltagen Ventures provides operational support and access to their network, helping portfolio companies navigate challenges and seize growth opportunities. They emphasize collaboration and mentorship to enhance the success of their investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.